TMPRSS2 was found to favor the immune escape of COVID-19 (Shang et al., 2020), and TMPRSS4 was upregulated in malignancies of the stomach (Tazawa et al., 2022), liver (Dong et al., 2020), and prostate (Lee et al., 2021). Here, TMPRSS4 is linked to COVID-19.